Clinical trials: Resectable Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation.
- Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
- Trial name
- NCT07538193
- Testing
- Iparomlimab and Tuvonralimab combined with Platinum-Based Chemotherapy (Pemetrexed/Carboplatin for Non-squamous; Nab-paclitaxel/Carboplatin for Squamous)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tang-Du Hospital
Non Small Cell Lung Cancer
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
- Trial name
- NCT05380024
- Testing
- Ensartinib
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer
Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB
This study aims to investigate the efficacy and safety of targeted therapy and chemotherapy±immunotherapy as neoadjuvant therapy in stage IIB-IIIB NSCLC patients.（observational study）
- Trial name
- NCT04197076
- Testing
- anti-PD-1 or anti-PD-L1, EGFR-TKI, ALK inhibitor, ROS1 inhibitor, investigator decided
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
NSCLC Stage II, NSCLC, Stage IIIA
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to…
- Conditions
- NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB
- Trial name
- iReP (NCT04865250)
- Testing
- Atezolizumab 1200 mg abs day 1 q22 (iv)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Lung Neoplasm Malignant
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or…
- Trial name
- NCT06788912
- Testing
- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine
- Where
- 39 sites in United States, Chile and 7 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
ALK-positive Non Small Cell Lung Cancer
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
This is a single-arm clinical study planning to enroll 30 treatment-naive patients with resectable ALK-positive non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07771764
- Testing
- iruplaltinib and pemetrexed
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Non Small Cell Lung Cancer, Stage I Lung Cancer
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7
- Trial name
- NCT03870529
- Testing
- Vitamin A Compound, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to…
- Conditions
- Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor
- Trial name
- TOASTIT (NCT04213794)
- Testing
- Cisplatin, Cytoreductive Surgery, Doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer Metastatic, Lung Diseases
PALACE: Cemiplimab Trial According to ctDNA Levels
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer
- Trial name
- PALACE (NCT06917573)
- Testing
- Cemiplimab, Carboplatin, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundación GECP
Non-Small Cell Lung Cancer, Anti Angiogenesis
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery…
- Trial name
- NCT06475755
- Testing
- Immunochemotherapy combined with antiangiogenic, Immunochemotherapy
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Tang-Du Hospital
Neoadjuvant Immunotherapy, NSCLC
Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
The neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%，which…
- Conditions
- Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy
- Trial name
- NCT07231575
- Testing
- SBRT, Immunotherapy, antiangiogenesis therapy
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Lung Cancer (NSCLC)
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
The primary objective of this study is to determine the feasibility of four weeks of preoperative antibody therapy with amivantamab.
- Trial name
- NEOpredict-EGF (NCT06784791)
- Testing
- Amivantamab Intravenous, Carboplatin/Pemetrexed
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- University Hospital, Essen
Carcinoma, Non-Small-Cell Lung
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer
This is a prospective single-center, open-label, phase II study evaluating the efficacy of sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable non-small cell lung cancer.
- Trial name
- PRIORITY (NCT06221462)
- Testing
- Sintilimab, Anlotinib
- Volunteers
- 30 people
- Sponsor
- Ningbo No.2 Hospital
Lung Cancer (NSCLC)
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
This study will investigate the relationship between respiratory and gut microbiome and PD-1/PD-L1 immune checkpoint inhibitor efficacy and immune-related adverse events (irAE) in patients with non-small cell lung cancer (Stage…
- Trial name
- NCT06613308
- Testing
- Neoadjuvant immunotherapy combined with chemotherapy, Neoadjuvant chemotherapy
- Volunteers
- 20 people
- Sponsor
- Capital Medical University
Non-small Cell Lung Cancer
Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
Concomitant chemoradiotherapy is the standard treatment of locally advanced,non-resectable, non-small cell lung cancer (NSCLC). However,the optimal chemotherapy regimen is still controversial.The objective of this study was to…
- Trial name
- RT0901 (NCT01091376)
- Testing
- Erlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer Stage IB (Resectable), Non-small Cell Lung Cancer Stage II (Resectable)
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer
Lung cancer is the chief cause of cancer death. The new standard-of-care (SOC) in operable lung cancer combines chemotherapy and an immune-stimulating drug before the surgery (neoadjuvant approach).
- Conditions
- Non-small Cell Lung Cancer Stage IB (Resectable), Non-small Cell Lung Cancer Stage II (Resectable), Non-small Cell Lung Cancer Stage ⅢA (Resectable)
- Trial name
- Pre-PLaN (NCT06250829)
- Testing
- Observational
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-small Cell Lung Cancer
Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)
Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable, non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial.
- Trial name
- NCT01158144
- Testing
- Endostar, Paclitaxel/Carboplatin
- Where
- 2 sites in China
- Volunteers
- 134 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Non-Small-Cell Lung
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC
This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.
- Trial name
- NCT07760519
- Testing
- IMFINZI
- Volunteers
- 78 people
- Sponsor
- AstraZeneca
Resectable Lung Non-Small Cell Carcinoma
Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer
This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes involving the middle of the chest.
- Trial name
- NCT06008730
- Testing
- Biospecimen Collection, Proton Beam Radiation Therapy, Radiology, Treatment Planning
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University